Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy

Glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients

H. Masuda, M. Sakamoto, Junichiro Irie, A. Kitaoka, K. Shiono, G. Inoue, K. Atsuda, Satoru Yamada

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective: The aim of this study was to evaluate twice-daily injections of biphasic insulin lispro vs. basal-bolus (BB) therapy with regard to quality-of-life (QOL) and glycaemic control in insulin-naïve type 2 diabetic patients. Methods: Twenty-eight patients with type 2 diabetes were randomized to receive either twice-daily 50/50 premixed insulin lispro (Mix50 group) or BB (NPH insulin at bedtime and preprandial insulin lispro) therapy (BB group) for 12 weeks. Glycated haemoglobin (HbA1C), 1,5-anhydroglucitol (1,5-AG), blood plasma glucose level, body mass index (BMI), daily total insulin dosage and insulin therapy-related QOL (ITR-QOL) were studied. Results: ITR-QOL was significantly better in the Mix50 than in the BB group (103.1 ± 9.8 vs. 90.6 ± 19.4; p < 0.05). HbA1c improved in both groups (from 11.1 ± 2.1 to 6.9 ± 1.0% with Mix50 vs. from 11.0 ± 2.3 to 6.6 ± 0.8% with BB therapy). Conclusion: These results might suggest that twice-daily injections of premixed rapid-acting insulin analogue therapy could achieve good glycaemic control and better QOL compared with BB therapy in insulin-naïve type 2 diabetes.

Original languageEnglish
Pages (from-to)1261-1265
Number of pages5
JournalDiabetes, Obesity and Metabolism
Volume10
Issue number12
DOIs
Publication statusPublished - 2008

Fingerprint

Insulin Lispro
Biphasic Insulins
Quality of Life
Insulin
Injections
Type 2 Diabetes Mellitus
Therapeutics
Short-Acting Insulin
Isophane Insulin
Glycosylated Hemoglobin A
Blood Glucose
Body Mass Index

Keywords

  • Insulin lispro
  • Insulin therapy
  • Quality-of-life
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy : Glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients. / Masuda, H.; Sakamoto, M.; Irie, Junichiro; Kitaoka, A.; Shiono, K.; Inoue, G.; Atsuda, K.; Yamada, Satoru.

In: Diabetes, Obesity and Metabolism, Vol. 10, No. 12, 2008, p. 1261-1265.

Research output: Contribution to journalArticle

@article{c638a5f037764d7baedd3af05f11a7f3,
title = "Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: Glycaemic control and quality-of-life of insulin-na{\"i}ve type 2 diabetic patients",
abstract = "Objective: The aim of this study was to evaluate twice-daily injections of biphasic insulin lispro vs. basal-bolus (BB) therapy with regard to quality-of-life (QOL) and glycaemic control in insulin-na{\"i}ve type 2 diabetic patients. Methods: Twenty-eight patients with type 2 diabetes were randomized to receive either twice-daily 50/50 premixed insulin lispro (Mix50 group) or BB (NPH insulin at bedtime and preprandial insulin lispro) therapy (BB group) for 12 weeks. Glycated haemoglobin (HbA1C), 1,5-anhydroglucitol (1,5-AG), blood plasma glucose level, body mass index (BMI), daily total insulin dosage and insulin therapy-related QOL (ITR-QOL) were studied. Results: ITR-QOL was significantly better in the Mix50 than in the BB group (103.1 ± 9.8 vs. 90.6 ± 19.4; p < 0.05). HbA1c improved in both groups (from 11.1 ± 2.1 to 6.9 ± 1.0{\%} with Mix50 vs. from 11.0 ± 2.3 to 6.6 ± 0.8{\%} with BB therapy). Conclusion: These results might suggest that twice-daily injections of premixed rapid-acting insulin analogue therapy could achieve good glycaemic control and better QOL compared with BB therapy in insulin-na{\"i}ve type 2 diabetes.",
keywords = "Insulin lispro, Insulin therapy, Quality-of-life, Type 2 diabetes",
author = "H. Masuda and M. Sakamoto and Junichiro Irie and A. Kitaoka and K. Shiono and G. Inoue and K. Atsuda and Satoru Yamada",
year = "2008",
doi = "10.1111/j.1463-1326.2008.00897.x",
language = "English",
volume = "10",
pages = "1261--1265",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy

T2 - Glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients

AU - Masuda, H.

AU - Sakamoto, M.

AU - Irie, Junichiro

AU - Kitaoka, A.

AU - Shiono, K.

AU - Inoue, G.

AU - Atsuda, K.

AU - Yamada, Satoru

PY - 2008

Y1 - 2008

N2 - Objective: The aim of this study was to evaluate twice-daily injections of biphasic insulin lispro vs. basal-bolus (BB) therapy with regard to quality-of-life (QOL) and glycaemic control in insulin-naïve type 2 diabetic patients. Methods: Twenty-eight patients with type 2 diabetes were randomized to receive either twice-daily 50/50 premixed insulin lispro (Mix50 group) or BB (NPH insulin at bedtime and preprandial insulin lispro) therapy (BB group) for 12 weeks. Glycated haemoglobin (HbA1C), 1,5-anhydroglucitol (1,5-AG), blood plasma glucose level, body mass index (BMI), daily total insulin dosage and insulin therapy-related QOL (ITR-QOL) were studied. Results: ITR-QOL was significantly better in the Mix50 than in the BB group (103.1 ± 9.8 vs. 90.6 ± 19.4; p < 0.05). HbA1c improved in both groups (from 11.1 ± 2.1 to 6.9 ± 1.0% with Mix50 vs. from 11.0 ± 2.3 to 6.6 ± 0.8% with BB therapy). Conclusion: These results might suggest that twice-daily injections of premixed rapid-acting insulin analogue therapy could achieve good glycaemic control and better QOL compared with BB therapy in insulin-naïve type 2 diabetes.

AB - Objective: The aim of this study was to evaluate twice-daily injections of biphasic insulin lispro vs. basal-bolus (BB) therapy with regard to quality-of-life (QOL) and glycaemic control in insulin-naïve type 2 diabetic patients. Methods: Twenty-eight patients with type 2 diabetes were randomized to receive either twice-daily 50/50 premixed insulin lispro (Mix50 group) or BB (NPH insulin at bedtime and preprandial insulin lispro) therapy (BB group) for 12 weeks. Glycated haemoglobin (HbA1C), 1,5-anhydroglucitol (1,5-AG), blood plasma glucose level, body mass index (BMI), daily total insulin dosage and insulin therapy-related QOL (ITR-QOL) were studied. Results: ITR-QOL was significantly better in the Mix50 than in the BB group (103.1 ± 9.8 vs. 90.6 ± 19.4; p < 0.05). HbA1c improved in both groups (from 11.1 ± 2.1 to 6.9 ± 1.0% with Mix50 vs. from 11.0 ± 2.3 to 6.6 ± 0.8% with BB therapy). Conclusion: These results might suggest that twice-daily injections of premixed rapid-acting insulin analogue therapy could achieve good glycaemic control and better QOL compared with BB therapy in insulin-naïve type 2 diabetes.

KW - Insulin lispro

KW - Insulin therapy

KW - Quality-of-life

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=55449093897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55449093897&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1326.2008.00897.x

DO - 10.1111/j.1463-1326.2008.00897.x

M3 - Article

VL - 10

SP - 1261

EP - 1265

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 12

ER -